Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2009 |
| End Date: | December 2015 |
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
The purpose of this observational study is to collect additional information regarding
long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical
practice.
long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical
practice.
Inclusion Criteria:
- Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical
care
Exclusion Criteria:
- Local regulations in some locations may exclude patients who receive Ilaris for a
non-approved indication
- Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials